Pushing estrogen receptor around in breast cancer

Abstract S6-01:PIK3CAstatus in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial:

(2016) J Baselga et al.   CANCER RESEARCH

Window-of-Opportunity Trials in the Preoperative Setting: Insights Into Drug Development for Estrogen Receptor–Positive Breast Cancer

(2016) Matthew P. Goetz et al.   JOURNAL OF CLINICAL ONCOLOGY

PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

(2016) Charlotte Fribbens et al.   JOURNAL OF CLINICAL ONCOLOGY

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

(2016) Ian E Krop et al.   LANCET ONCOLOGY

Cooperative Dynamics of AR and ER Activity in Breast Cancer

(2016) N. C. D'Amato et al.   MOLECULAR CANCER RESEARCH

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

(2016) Jill M. Spoerke et al.   Nature Communications

Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer

(2016) Sarat Chandarlapaty et al.   JAMA Oncology

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer

(2015) J. O'Shaughnessy et al.   ANNALS OF ONCOLOGY

St. Gallen endocrine response classes predict recurrence rates over time

(2015) R.H.T. Koornstra et al.   BREAST

Abstract P1-13-04: Enobosarm for the treatment of metastatic, estrogen and androgen receptor positive, breast cancer. Final results of the primary endpoint and current progression free survival

(2015) Beth Overmoyer et al.   CANCER RESEARCH

The intracrinology of breast cancer

(2015) Keely May McNamara et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

(2015)   LANCET

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

Progesterone receptor modulates ERα action in breast cancer

(2015) Hisham Mohammed et al.   NATURE

ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer

(2015) Rinath Jeselsohn et al.   Nature Reviews Clinical Oncology

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the Androgen Receptor in Breast Cancer

(2015) KeeMing Chia et al.   Current Oncology Reports

DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer

(2015) Andrew Stone et al.   Nature Communications

10P * A PHASE 1 OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ENZALUTAMIDE ALONE OR COMBINED WITH AN AROMATASE INHIBITOR IN WOMEN WITH ADVANCED BREAST CANCER

(2014) T. A. Traina et al.   ANNALS OF ONCOLOGY

Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial†

(2014) J. Bines et al.   ANNALS OF ONCOLOGY

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†

(2014) M. Piccart et al.   ANNALS OF ONCOLOGY

Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight

(2014) Suzanne A. W. Fuqua et al.   BREAST CANCER RESEARCH AND TREATMENT

AR collaborates with ERα in aromatase inhibitor-resistant breast cancer

(2014) Yassine Rechoum et al.   BREAST CANCER RESEARCH AND TREATMENT

Complexities of androgen receptor signalling in breast cancer

(2014) Keely M McNamara et al.   ENDOCRINE-RELATED CANCER

Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma

(2014) Rika Fujii et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Selective androgen receptor modulators as improved androgen therapy for advanced breast cancer

(2014) Christopher C. Coss et al.   STEROIDS

Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer

(2013) W. Jonat et al.   ANNALS OF ONCOLOGY

A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer

(2013) R. Charles Coombes et al.   BREAST CANCER RESEARCH AND TREATMENT

Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study

(2013) C A Purdie et al.   BRITISH JOURNAL OF CANCER

Expression of androgen receptor and its phosphorylated forms in breast cancer progression

(2013) Qinghu Ren et al.   CANCER

Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer

(2013) A. Gucalp et al.   CLINICAL CANCER RESEARCH

Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers

(2013) Isabell Witzel et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Effect of an investigational CYP17A1 inhibitor, orteronel (TAK-700), on estrogen- and corticoid-synthesis pathways in hypophysectomized female rats and on the serum estradiol levels in female cynomolgus monkeys

(2013) Masuo Yamaoka et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

An International Ki67 Reproducibility Study

(2013) Mei-Yin C. Polley et al.   JNCI-Journal of the National Cancer Institute

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial

(2013) Adrian S Dobs et al.   LANCET ONCOLOGY

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

(2013) Weiyi Toy et al.   NATURE GENETICS

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

(2013) Dan R Robinson et al.   NATURE GENETICS

Reduced Androgen Receptor Expression Accelerates the Onset of ERBB2 Induced Breast Tumors in Female Mice

(2013) Myles C. Hodgson et al.   PLoS One

Endogenous Purification Reveals GREB1 as a Key Estrogen Receptor Regulatory Factor

(2013) Hisham Mohammed et al.   Cell Reports

Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation

(2012) Matthew J. Sikora et al.   BREAST CANCER RESEARCH AND TREATMENT

Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study

(2012) John F. R. Robertson et al.   BREAST CANCER RESEARCH AND TREATMENT

Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures

(2012) Peter Kabos et al.   BREAST CANCER RESEARCH AND TREATMENT

AIB1:ER  Transcriptional Activity Is Selectively Enhanced in Aromatase Inhibitor-Resistant Breast Cancer Cells

(2012) J. O'Hara et al.   CLINICAL CANCER RESEARCH

An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity

(2012) Nicole L Moore et al.   ENDOCRINE-RELATED CANCER

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

(2012) Thomas Bachelot et al.   JOURNAL OF CLINICAL ONCOLOGY

Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys

(2012) Masuo Yamaoka et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Minireview: The Androgen Receptor in Breast Tissues: Growth Inhibitor, Tumor Suppressor, Oncogene?

(2012) T. E. Hickey et al.   MOLECULAR ENDOCRINOLOGY

Whole-genome analysis informs breast cancer response to aromatase inhibition

(2012) Matthew J. Ellis et al.   NATURE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

(2012) Christina Curtis et al.   NATURE

Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer

(2012) Rita S. Mehta et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical importance of androgen receptor in breast cancer patients treated with adjuvant tamoxifen monotherapy

(2012) Naoko Honma et al.   Breast Cancer

Androgen Resistance in Female Mice Increases Susceptibility to DMBA-Induced Mammary Tumors

(2012) Ulla Simanainen et al.   Hormones & Cancer

Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer

(2011) Tomohiro Kaku et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy

(2011) Sibylle Loibl et al.   BREAST CANCER RESEARCH AND TREATMENT

Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer

(2011) Min Ni et al.   CANCER CELL

Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women

(2011) R. Hu et al.   CLINICAL CANCER RESEARCH

Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1

(2011) Jessica L L Robinson et al.   EMBO JOURNAL

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer

(2011) C. Thangavel et al.   ENDOCRINE-RELATED CANCER

Differential Effects of Exogenous Androgen and an Androgen Receptor Antagonist in the Peri- and Postpubertal Murine Mammary Gland

(2011) A. A. Peters et al.   ENDOCRINOLOGY

Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer

(2011) Carlo Palmieri et al.   Expert Review of Anticancer Therapy

Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy

(2011) Ashley Cimino-Mathews et al.   HUMAN PATHOLOGY

Single-Injection Depot Progesterone Before Surgery and Survival in Women With Operable Breast Cancer: A Randomized Controlled Trial

(2011) Rajendra Badwe et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer

(2011) Jack Cuzick et al.   JOURNAL OF CLINICAL ONCOLOGY

Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study

(2011) Laura C Collins et al.   MODERN PATHOLOGY

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial

(2011) James T. Dalton et al.   Journal of Cachexia Sarcopenia and Muscle

Expression of androgen receptor in breast cancer and its significance as a prognostic factor

(2010) Q. Yu et al.   ANNALS OF ONCOLOGY

Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers

(2010) Isabella Castellano et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with hormone responsive advanced breast cancer: no evidence of a pharmacokinetic interaction between exemestane and fulvestrant.

(2010) E Mrozek et al.   CANCER RESEARCH

FOXA1 is a key determinant of estrogen receptor function and endocrine response

(2010) Antoni Hurtado et al.   NATURE GENETICS

Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers

(2010) Donata Micello et al.   VIRCHOWS ARCHIV

Additive endocrine therapy for advanced breast cancer – back to the future

(2009) Per Eystein Lønning   ACTA ONCOLOGICA

Expression of androgen receptors in primary breast cancer

(2009) S. Park et al.   ANNALS OF ONCOLOGY

Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations

(2009) C. Schneider et al.   CLIMACTERIC

Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer

(2009) A. M. Gonzalez-Angulo et al.   CLINICAL CANCER RESEARCH

Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

(2009) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Nonsteroidal Selective Androgen Receptor Modulators (SARMs): Dissociating the Anabolic and Androgenic Activities of the Androgen Receptor for Therapeutic Benefit

(2009) Michael L. Mohler et al.   JOURNAL OF MEDICINAL CHEMISTRY

Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation

(2009) Leo A Niemeier et al.   MODERN PATHOLOGY

Structural basis for androgen specificity and oestrogen synthesis in human aromatase

(2009) Debashis Ghosh et al.   NATURE

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

(2009) C. Tran et al.   SCIENCE

Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: A randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C)

(2008) Jørn Andersen et al.   ACTA ONCOLOGICA

The androgen metabolite 5α-androstane-3β,17β-diol (3βAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance

(2008) Matthew J. Sikora et al.   BREAST CANCER RESEARCH AND TREATMENT

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

(2008)   LANCET ONCOLOGY

Steroidal Androgens and Nonsteroidal, Tissue-Selective Androgen Receptor Modulator, S-22, Regulate Androgen Receptor Function through Distinct Genomic and Nongenomic Signaling Pathways

(2008) Ramesh Narayanan et al.   MOLECULAR ENDOCRINOLOGY